or Try an Advanced Search...

    Technical Analysis for RGLS - Regulus Therapeutics Inc.

    Grade Last Price % Change Price Change
    F 1.40 -1.41% -0.02
    RGLS closed down 1.41 percent on Wednesday, November 20, 2024, on 39 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical RGLS trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    Oversold Stochastic Weakness 0.00%
    Calm After Storm Range Contraction -1.41%
    Lower Bollinger Band Walk Weakness -1.41%
    Stochastic Reached Oversold Weakness -1.41%
    BB Squeeze Ended Range Expansion -1.41%
    Gapped Down Weakness -1.41%
    Lower Bollinger Band Touch Weakness -1.41%
    Oversold Stochastic Weakness -1.41%
    MACD Bearish Signal Line Cross Bearish -1.41%
    Older End-of-Day Signals for RGLS ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 18 hours ago
    Possible NR7 about 18 hours ago
    Down 2 % about 19 hours ago
    Down 1% about 22 hours ago
    Up 1% about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    RGLS Chart by TradingView
    Basic chart:

    Profile

    Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Disease Genetics Blastoma Glioblastoma Carcinoma Hepatitis C Hepatitis C Virus Hepatocellular Carcinoma Oligonucleotide RNA Regulus Therapeutics Alnylam Pharmaceuticals Nucleic Acids Atherosclerosis Hepatitis C Virus Infection Nucleotides

    Is RGLS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 7 Regulus Therapeutics GAAP EPS of -$0.21 misses by $0.04
    Nov 7 Regulus: Q3 Earnings Snapshot
    Nov 7 Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
    Oct 29 These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts
    Oct 8 Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Aug 14 Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth
    Aug 8 Regulus Therapeutics GAAP EPS of -$0.17 misses by $0.02
    Aug 8 Regulus: Q2 Earnings Snapshot
    Aug 8 Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
    Aug 6 Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
    See more RGLS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.79
    52 Week Low 1.08
    Average Volume 385,044
    200-Day Moving Average 1.88
    50-Day Moving Average 1.54
    20-Day Moving Average 1.48
    10-Day Moving Average 1.46
    Average True Range 0.11
    RSI (14) 41.86
    ADX 11.18
    +DI 17.14
    -DI 18.29
    Chandelier Exit (Long, 3 ATRs) 1.36
    Chandelier Exit (Short, 3 ATRs) 1.68
    Upper Bollinger Bands 1.59
    Lower Bollinger Band 1.37
    Percent B (%b) 0.13
    BandWidth 14.53
    MACD Line -0.03
    MACD Signal Line -0.02
    MACD Histogram -0.006
    Fundamentals Value
    Market Cap 28.31 Million
    Num Shares 20.2 Million
    EPS -1.59
    Price-to-Earnings (P/E) Ratio -0.88
    Price-to-Sales 7.43
    Price-to-Book 1.12
    PEG Ratio -0.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.48
    Resistance 3 (R3) 1.49 1.46 1.47
    Resistance 2 (R2) 1.46 1.44 1.46 1.46
    Resistance 1 (R1) 1.43 1.43 1.42 1.43 1.46
    Pivot Point 1.41 1.41 1.40 1.41 1.41
    Support 1 (S1) 1.38 1.39 1.37 1.37 1.34
    Support 2 (S2) 1.35 1.37 1.35 1.34
    Support 3 (S3) 1.32 1.35 1.33
    Support 4 (S4) 1.32